The central and peripheral hemodynamics of celiprolol
Related Experiment Videos
1Cattedra di Semeiotic Medica e Istitudo di Clinica Medica, Generale e Terapia Medica, Universita di Milano, Centro di Fisiologia, Clinica e Ipertensione, Italy.
Insights
Celiprolol offers cardiovascular benefits by causing vasodilation and maintaining cardiac function during exercise, unlike traditional beta-blockers. This drug effectively reduces blood pressure, particularly in hypertensive patients, by improving vascular resistance and renal blood flow.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Cardiovascular disease and hypertension remain leading global health concerns.
- Traditional beta-blockers can negatively impact cardiac contractility and exercise capacity.
- Celiprolol represents a distinct class of beta-blockers with a unique pharmacological profile.
Purpose of the Study:
- To review the cardiovascular effects of celiprolol.
- To compare celiprolol's actions with classic beta-blockers.
- To elucidate the mechanisms behind celiprolol's antihypertensive effects.
Main Methods:
- Review of existing clinical studies and pharmacological data.
- Analysis of celiprolol's impact on cardiac contractility at rest and during exercise.
- Assessment of celiprolol's effects on systemic vascular resistance and renal hemodynamics.
Main Results:
- Celiprolol preserves resting cardiac contractility and minimally affects exercise cardiac function.
- The drug induces systemic vasodilation, primarily reducing blood pressure in hypertensive individuals.
- Celiprolol enhances renal blood flow by reducing vascular resistance, preventing salt and water retention.
Conclusions:
- Celiprolol demonstrates a favorable cardiovascular profile compared to classic beta-blockers.
- Its antihypertensive efficacy is linked to systemic vasodilation and preserved renal perfusion.
- Additional properties beyond selective beta1-receptor blockade may contribute to celiprolol's hemodynamic effects.
Abstract:
The cardiovascular effects of celiprolol in healthy subjects and in those with cardiovascular disease and hypertension are reviewed. Unlike classic beta-blockers, celiprolol does not depress cardiac contractility at rest while interfering to a lesser extent with cardiac function during exercise. Furthermore, celiprolol causes systemic vasodilatation, which, in hypertension, is mainly responsible for the blood pressure-reducing effects of the drug. Vasodilatation results from the reduction in vascular resistance of skeletal muscle tissues, but celiprolol also produces dilatation of vascular areas such as the kidney. This prevents a reduction in renal blood flow and consequently the salt and water retention associated with impaired perfusion. It is possible that such hemodynamic changes are dependent not on celiprolol's selective beta1-receptor-blocking properties but on certain additional properties.